Trial: 201907150

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)

Phase

III

Principal Investigator

Schroeder, Mark

Disease Site

Multiple Myeloma

Learn more about this study at: clinicaltrials.gov